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35 ABSTRACT 
 
36 Aim: To determine whether self-management interventions, including regular home exercise, 
 
37 can offer favorable outcomes for older adults with advanced chronic obstructive pulmonary 
 
38 disease (COPD) using long-term oxygen therapy (LTOT). 
 
 
39 Methods: Information was provided to improve COPD self-management prior to the onset of 
 
40 this prospective three-year cohort study. Patients selected either a home-based exercise 
 
41 intervention using a lower-limb cycle machine (ergo-bicycle) (Group E), or usual exercise 
 
42 (Group U). To assess self-management interventions, the Lung Information Needs 
 
43 Questionnaire (LINQ) was evaluated every 6 months. Clinical outcomes included six-minute 
 
44 walk test (6MWT), pulmonary function tests, the BODE index, St. George’s respiratory 
 
45 questionnaire, and the number of exacerbations and hospitalizations. 
 
 
46 Results: A total of 136 patients (Group E = 72; Group U = 64), with a mean age of 74.2 years 
 
47 were enrolled. Total LINQ scores improved over three years for Group E (p=.003). The 
 
48 distance of the 6MWT was well maintained in Group E, but significantly decreased in Group 
 
49 U (p<.001). Percentage of forced expiratory volume per second at baseline was lower in 
 
50 Group E (p=.016) but was maintained over three years, whereas a significant reduction was 
 
51 seen in Group U (p=.001). The BODE index significantly worsened in both groups over three 
 
52 years (Group E: p=.011; Group U: p<.001), while a significant decrease in the number of 
 
53 exacerbations was noted in Group E (p=.009). 
 
 
54 Conclusions: Positive outcomes were observed in older COPD patients on LTOT who 
 
55 undertook exercise training with ergo-bicycle machine compared to those who chose usual 
 
56 care at home. 
 
 
57 Key words: COPD; home-based exercise; long-term oxygen therapy; patient education; 
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58 self-management. 
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60 
 
61 INTRODUCTION 
 
62 In an aging population, chronic obstructive pulmonary disease (COPD) is a major cause of 
 
63 morbidity and mortality [1]. Among various COPD symptoms for older adults, dyspnea on 
 
64 exertion is associated with the highest risk of disability and death. Important factors affecting 
 
65 older COPD patients include medication adherence, caregiver involvement, and the incidence 
 
66 of multiple comorbidities, such as cognitive impairment [2,3]. 
 
 
67 Extra-pulmonary manifestations include systemic complications and COPD-associated 
 
68 skeletal muscle dysfunction that includes weakness and atrophy in the lower limbs as a 
 
69 consequence of physical inactivity [4]. Physical exercise is an effective means of managing 
 
70 dyspnea on exertion and preventing sarcopenia, which is prevalent in older patients with 
 
71 COPD [1,5]. Nonetheless, poor physical function has been linked to the incidence of hypoxia 
 
72 in patients with advanced COPD [6]. Insofar, pulmonary rehabilitation offers the best 
 
73 management strategy to rehabilitate patients with COPD [5,7,8]; improvement of muscle 
 
74 strength in the lower extremities is assumed to lead to better exercise tolerance and 
 
75 health-related quality of life [9]. The reduction in muscle power in the lower extremities is 
 
76 likely to be a systemic effect of COPD [9]. However, to our knowledge, little is known 
 
77 regarding the efficacy of self-management interventions for older COPD patients, particularly 
 
78 for those in the advanced stages [1]. 
 
 
79 In our previous study [10], we concluded that the use of patient information for integrative 
 
80 care and patient self-management, as assessed by the Lung Information Needs Questionnaire 
 
81 (LINQ) [11], can improve patient information needs and health outcomes. Recently, Jonkman 
 
82 et al. reported that longer duration of self-management interventions conferred better clinical 
 
83 outcome [12], although sufficient data are still lacking. 
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84 We hypothesized that a home-based, lower-limb endurance training program can provide 
 
85 positive outcomes as an adjunctive treatment to long-term oxygen therapy (LTOT) in older 
 
86 and advanced COPD patients. 
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87 METHODS 
 
 
88 In this prospective cohort study, we recruited patients between January 2008 and 
 
89 December 2012 from the Respiratory Care Clinic, which is a secondary referral clinic 
 
90 affiliated with the Nippon Medical School, Tokyo, Japan. The enrolled patients were over 65 
 
91 years old, and were included if they had the following: dyspnea on exertion, and cough 
 
92 and/or sputum; a history of long-term smoking; a stable condition for at least three months 
 
93 prior to the study; and those receiving LTOT according to the criteria defined by the Japan 
 
94 Respiratory Society [13]. A clinical diagnosis of COPD was derived from the GOLD 
 
95 guidelines [1]. Medication was based on triple therapy [14], which included long-acting 
 
96 muscarinic antagonist, long-acting β2-agonist, and inhaled corticosteroid. Patients with 
 
97 contraindications, such as cholinergic regimens, or patients with prostate hypertrophy were 
 
98 not included. Continuous oxygen therapy was prescribed for more than 15 hours per day [1], 
 
99 with an oxygen concentrator at the patients’ residence to supply oxygen. Patients receiving 
 
100 LTOT were instructed on a monthly basis by their physician, according to the medical 
 
101 insurance regulation in Japan [13]. Patients with cardiovascular diseases, including 
 
102 exercise-related risk factors such as unstable hypertension, severe aortic regurgitation, or 
 
103 comorbid respiratory diseases, such as severe bronchiectasis or lung fibrosis, were excluded 
 
104 by clinical history or appropriate examinations. 
 
 
105 Cognitive function examinations were performed using the Mini Mental State 
 
106 Examination (MMSE) [15]; patients scoring <26 were excluded from this study. The ethics 
 
107 committee of the Nippon Medical School approved this study, and all patients were required 
 
108 to provide written informed consent prior to enrollment. 
 
 
109 
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110 Study design 
 
 
111 The enrolled subjects received equal instruction for comprehensive self-management, 
 
112 regardless of their group, delivered by physicians and other health care professionals [16]. 
 
113 Additionally, they were regularly assessed via LINQ [11]. LINQ assesses the patient’s 
 
114 information needs on the following six domains: an understanding of COPD; medication; 
 
115 avoidance of exacerbations; smoking cessation; daily exercise; and nutritional support. The 
 
116 medical staff re-evaluated the LINQ scores every six months, and tailored patient instruction 
 
117 were provided to the patients. These instructions were based on the individual’s responses, 
 
118 and included additional information or correction of misinformation for self-management. 
 
 
119 Participants chose either home-based exercises using a lower-limb cycle machine 
 
120 (ergo-bicycle) (Group E), or usual exercises (Group U). Both groups were requested to keep a 
 
121 written diary so that a respiratory nurse could deliver encouragement and advice at each 
 
122 clinic visit. 
 
 
123 Patients in Group E were obliged to purchase an ergo-bicycle, and asked to follow 
 
124 operating instructions. Group E patients were instructed to use the ergo-bicycle once per day, 
 
125 for at least 20 min, with oxygen inhalation. Exercise was performed at minimum resistance at 
 
126 the beginning of the study with addition of incremental resistance as the study progressed, 
 
127 based on the patient’s maximum pulse rate and subjective assessment of dyspnea obtained 
 
128 from their diaries. The patients were requested to increase their pulse rates during exercise to 
 
129 80% of their maximum pulse rate during a six-minute walk test [17]. 
 
 
130 Group U patients were instructed to exercise once a day for at least 20 min [16]. The 
 
131 patients were encouraged to exercise more frequently, and for longer durations, if possible. 
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132 The exercise intensity was set at either 3 or 4, based on the Borg scale. Patients with portable 
 
133 oxygen cylinders were instructed to use oxygen during exercise. 
 
 
134 Patients were to suspend training if they experienced the following events: fever (>37°C), 
 
135 increased dyspnea, body pain such as lumbago, arthralgia, or a worsening of comorbidities. 
 
136 After each exercise session, approximately 5-10 min of cooling-down time was provided for 
 
137 both groups. Patients could call at the respiratory clinic if they felt concerned during exercise. 
 
 
138 
 
 
139 
 
140 
Clinical Examinations and Outcome Measurements 
 
141 Pulmonary function tests: The Chestac-55 (Chest Co., Tokyo, Japan) was used to measure the 
 
142 pulmonary function parameters, including post-bronchodilator forced expiratory volume in 1 
 
143 second (FEV1), vital capacity, and forced vital capacity, according to the guidelines of the 
 
144 American Thoracic Society (ATS) [18]. The predicted values were calculated according to 
 
145 
 
146 
the reference values from the Japanese Respiratory Society [19]. 
 
147 Dyspnea scale: The severity of dyspnea was evaluated by the modified Medical Research 
 
148 
 
149 
Council dyspnea scale (MMRC) [20]. 
 
150 Exercise capacity: The six-minute walk test (6MWT) was performed according to standard 
 
151 
 
152 
guidelines as previously reported [21]. 
 
153 Body mass index: The body mass index (BMI) was calculated as the ratio of weight in 
 
154 
 
155 
kilograms to height in square meters. 
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156 BODE index: Disease severity of COPD was assessed using the BMI, airflow obstruction, 
 
157 severity of dyspnea, and exercise capacity. The BODE index is a multi-dimensional grading 
 
158 system that predicts mortality, hospitalization, risk of exacerbations, and reflects the 
 
159 detrimental changes that occur during exacerbation in COPD [22]. The total score ranges 
 
160 
 
161 
from 0 to 10 points, and a high BODE score indicates a high risk of death. 
 
162 Lung Information Needs Questionnaire: The LINQ is a self-completed questionnaire that 
 
163 
 
164 
measures the information needs of patients with COPD [11]. 
 
165 Health status: The disease-specific health status of the patient was assessed using the St 
 
166 
 
167 
George’s Respiratory Questionnaire (SGRQ) [23], Japanese version. 
 
168 Comorbidities: Comorbidities were measured using the Charlson index [24], which is 
 
169 
 
170 
associated with mortality in COPD as previously reported [25]. 
 
 
171 Outcome measurements: Incidences of exacerbations and hospitalizations were recorded 
 
172 during monthly outpatient clinic visits. Exacerbations were defined as an increase in the 
 
173 severity of the following respiratory symptoms: dyspnea; cough and sputum volume; and 
 
174 sputum purulence that leads to a change in medication, such as antibiotics or systemic 
 
175 corticosteroids, or the admission to hospital [1]. 
 
 
176 
 
 
177 Statistical Analysis 
 
178 To determine the sample size, a power calculation was performed for the outcomes and the 
 
179 total LINQ score. In our preliminary analysis, the distribution of the total LINQ scores had a 
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180 standard deviation (SD) of 4.28. The required sample size was 100 patients (50 patients per 
 
181 group) for the detection of a difference of 2.80 or larger in the total LINQ score with an alpha 
 
182 level of 0.05, 1-β 0.90, and the SD. As we anticipated a 25% dropout rate, we initially 
 
183 planned to assign 130 patients. 
 
184 We calculated the mean, SD, and tested differences between Group U and Group E using 
 
185 paired t-tests. A p-value <.05 was considered significant. Repeated measures of two-way 
 
186 analysis of variance (ANOVA) were used to test the differences over time and between 
 
187 groups. Data were analyzed with the Statistical Package for the Social Sciences, version 22.0 
 
188 for Windows (SPSS Inc., Chicago, Illinois, U.S.A.). 
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189 RESULTS 
 
190 A detailed flow chart of this study is shown in Figure 1. The total number of patients 
 
191 recruited was 136, out of which 64 patients selected Group U due to economic considerations 
 
192 (16), limited home space for equipment (6), lower joint or back pain (11), or other exercises 
 
193 (31). The patient dropout rate over three years was 25 (39.1%) and 14 (19.4 %) for Groups U 
 
194 and E, respectively, (p=.007). The main reasons for patient withdrawal were transference to 
 
195 another hospital or comorbidity. There were no accidental or unexpected events during 
 
196 exercise for either group over the three-year study. 
 
 
197 The baseline characteristics between the groups are shown in Table 1. Group U patients 
 
198 (mean age: 76.1±7.3 years old) were significantly older than those in Group E (mean age: 
 
199 72.5±5.9 years old) (p=.002). There were no significant differences evident for the patients’ 
 
200 sex, 6MWT distance, MMRC dyspnea score, BMI, SGRQ score or LINQ score at the study 
 
201 baseline. In addition, no significant differences in the prevalence of comorbidities were 
 
202 observed between the patients, as evident from the Charlson Index, which included 33 and 41 
 
203 cases of cardiovascular disease in Group U and Group E, respectively. 
 
 
204 The total LINQ score in Group E significantly improved over three years (p=.003) 
 
205 whereas no change was evident for Group U (Table 2). The changes in the total score, and in 
 
206 the six LINQ domains at baseline, and at the first, second, and third year are shown in Table 
 
207 2. The avoidance of exacerbation domain significantly improved in Group E over three years 
 
208 (p<.001). In comparing between groups, a significant difference were seen over three years 
 
209 for the exacerbation domain (p=.002). Both groups showed improvements for the exercise 
 
210 domain over three years (Group U and E; p=.009 and p=.017, respectively). 
 
 
211 At baseline, the predicted FEV1% was consistently and significantly lower in Group E 
 
212 (p=.016) (Table 3), whereas a marked decrease was observed for Group U (p=.001) (Fig. 2). 
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213 For Group E, the predicted FEV1% decreased by 0.14±7.59%, whereas Group U decreased 
 
214 by 5.01±7.08% over three years. The predicted ΔFEV1% significantly differed between 
 
215 Groups E and U (p=.004). 
 
 
216 The distance covered by patients in 6MWT differed significantly between the two groups 
 
217 over three years (p=.014) (Fig. 2); the distance in Group E was maintained, whereas Group U 
 
218 patients showed a significant decrease (p<.001). Additionally, a significant decrease 
 
219 (47.7±50.4 m) for 6MWTD was also evident between the first and third years for Group U 
 
220 (p=.006). Conversely, the distance covered by Group E decreased by 11.5±67.8 m over three 
 
221 years. 
 
 
222 The MMRC score for each group worsened over three years, but there were no major 
 
223 differences between the groups from baseline to the third year (Fig. 2). 
 
 
224 The patients’ BMI showed a gradual decrease but a year-to-year difference was not evident 
 
225 between the groups; however, Group U patients had a significant decrease in the mean BMI 
 
226 until the third year (p=.006) (Table 3). 
 
 
227 An increase was noted for the BODE index scores for Groups U and E during the study 
228 (p<.001 and p=.011, respectively), however, no difference was observed between the groups 
229 over the three years (Fig. 2). 
 
 
230 The number of exacerbations significantly decreased in Group E (p=.009) during the 
 
231 study; however, there was no significant difference evident between the groups over the study 
 
232 period. Furthermore, no differences were seen for the number of hospitalizations between two 
 
233 groups over three years. 
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234 DISCUSSION 
 
 
235 The present study revealed several interesting observations regarding the self-management 
 
236 of COPD in older adult patients. The concept of LINQ is based on the premise that both 
 
237 information and knowledge are required for self-management interventions for COPD 
 
238 patients [11]. Although the total LINQ scores tended to improve over the first two years, they 
 
239 worsened for Group U over the third year. Furthermore, improvements were noted in the 
 
240 scores of the exercise domain of the LINQ assessment for both groups; however, the distance 
 
241 on the 6MWT decreased sharply in Group U compared to that in Group E. Although the 
 
242 patients in Group U were unable to maintain their baseline exercise capacity, the LINQ scores 
 
243 revealed that the patients improved their information needs on the exercise domain. This 
 
244 discrepancy raises two different possibilities. In a study on the expectancy, adherence, and 
 
245 perceived effort and benefit of medical interventions, Gaitan-Sierra and Hyland 
 
246 [26] concluded that placebo effects were mediated via the affective consequences of 
 
247 performing a motivated ritual, in a therapeutic context. In the present study, the use of the 
 
248 ergo-bicycle may have increased the positive affect during exercise because it is a novel and 
 
249 attractive device. The positive affect would then have increased effort and enjoyment, leading 
 
250 increased exercise as well as non-specific benefits of increased positive affect. Nonetheless, 
 
251 we evaluated neither the motivation nor expectations of the Group E patients towards the use 
 
252 of new therapeutic modalities. Each patient repeatedly received advice from health care 
 
253 professionals, based on their LINQ responses, and were encouraged to continue the 
 
254 self-management interventions, including the use of the home-based bicycle-ergometer for 
 
255 those in Group E. Although selecting the most effective method is important for maximizing 
 
256 the patient’s quality of life, healthcare providers are occasionally challenged by older patients. 
 
257 Previously, these difficulties were reported in patients with comorbidities, or those 
 
258 undergoing invasive cardiac surgery [27] or chemotherapy for malignancy [28]. This may be 
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259 accounted for by the inadequate strategies for disease management and symptoms, 
 
260 maintenance of functional status, and minimization of toxicity for older patients, particularly 
 
261 those over 75 years old. 
 
 
262 Bourbeau et al. [29] indicated that when patient knowledge and skills improve, 
 
263 self-efficacy can play a part in determining which activities or situations an individual will 
 
264 perform or avoid. Although the patients in Group U understood the importance of daily 
 
265 exercise for the self-management of COPD, they were either unable or unwilling to continue 
 
266 usual exercise training, which may account for their higher rate of exacerbations compared to 
 
267 those in Group E. Further, Group E patients had lower information needs on the LINQ 
 
268 domain for the avoidance of exacerbation. Therefore, they may have been better adapted to 
 
269 integrate self-management skills into their daily life, and differ in their perception of 
 
270 self-efficacy. Additionally, the patients who selected ergo-bicycle therapy were significantly 
 
271 younger, and had a lower dropout rate; however, these patients also had more severe airflow 
 
272 obstruction. Although we did not study the patient’s rationale for selecting ergo-bicycle 
 
273 therapy in detail, it was likely that the patients in Group U were less motivated, more 
 
274 depressive, or had difficulty predicting the treatment outcome. This may be due to the 
 
275 functional decline associated with aging and/or the reduction in overall motivation 
 
276 characteristic of older adults, which may warrant further study. 
 
 
277 The total LINQ scores improved, particularly for the exercise domain, over three years for 
 
278 both groups. Nonetheless, the mean distance covered by the patients of Group U for the 
 
279 6MWT decreased significantly by 47.7 m over three years,. This indicated that the use of the 
 
280 ergocycle significantly benefitted the patients in Group E. Intriguingly, the scores for the 
 
281 BODE index declined over the clinical course. The mean BODE index score significantly 
 
282 worsened for both groups over three years. Nonetheless, it was noted that the rate of change 
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283 in the BODE index scores for Group E was more gradual compared to that of Group U. The 
 
284 main factors that influenced this observation are attributable to the increase in the MMRC 
 
285 scores of the patients, which was indicative of increased dyspnea on daily movements. Thus, 
 
286 the relief of dyspnea during daily movements necessitates a viable treatment option, 
 
287 particularly for older patients with COPD, as current medications have shown limited 
 
288 therapeutic efficacy for COPD [1]. 
 
 
289 There were several limitations in this study. First, we were unable to precisely establish the 
 
290 patient’s intensity as they used the home-based, lower-limb training machine unsupervised. 
 
291 Second, the patients were not randomly allocated into groups. Nonetheless, this study design 
 
292 may have been more representative of real world circumstances. 
 
 
293 In conclusion, patients undertaking exercise training were able to maintain pulmonary 
 
294 function and exercise capacity, and experienced fewer exacerbations over the three-year study 
 
295 period. Positive outcomes were also observed in older patients with COPD who were using 
 
296 LTOT and exercise training with an ergo-bicycle machine as an adjunctive treatment at home. 
 
 
297 
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380 Table 1. Patient characteristics at baseline 
 
 Group U Group E  
p-value 
n=64 n=72  
Age 76.13±7.27 72.49±5.94 .002 
Male / Female 57 / 7 66 / 6 .772 
Smoking Ex / Current 59 / 5 71 / 1 .099 
COPD / ACOS / CPFE 48 / 12 / 4 51 / 16 / 5 .859 
Cardio diseases 33 41 .606 
Charlson Index (range 0-33) 3.33±1.33 2.97±1.34 .124 
Pulmonary function 
   
VC, L 2.84±0.80 2.97±0.73 .337 
%VC, % 87.26±19.07 87.51±19.40 .941 
FVC, L 2.79±0.80 2.90±0.72 .389 
FEV1, L 1.38±0.56 1.27±0.46 .198 
FEV1 %, % 50.85±17.83 43.41±10.45 .004 
FEV1, %predict, % 56.34±21.77 48.16±16.15 .016 
 
6MWT 
   
Distance, m 403.69±106.86 425.04±91.99 .214 
Minimum SpO2, % 87.13±6.25 85.89±5.33 .216 
Δ SpO2 8.56±5.68 9.35±4.83 .384 
Maximum pulse rate 113.48±17.82 118.23±16.36 .110 
Δ Pulse 28.48±13.77 30.68±13.50 .353 
Borg scale 4.00±2.29 4.43±2.06 .253 
MMRC (range 0-4) 1.60±1.02 1.64±1.02 .796 
BMI 21.12±3.34 21.45±4.17 .627 
SGRQ (range 0-100) 38.10±15.85 39.04±14.03 .772 
LINQ (range 0-25) 7.78±3.12 7.25±3.28 .437 
Number of exacerbations / year 1.23±1.10 1.35±1.28 .584 
Number of hospitalizations / year 0.19±0.59 0.19±0.43 .937 
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382 
 
 
Definition of abbreviations: COPD = chronic obstructive pulmonary disease, ACOS = 
 
383 asthma-COPD overlap syndrome, CPFE = combined pulmonary fibrosis and emphysema, VC 
 
384 = vital capacity, FVC = forced vital capacity, FEV1 = forced expiratory in 1 second, 6MWT 
 
385 = 6-minute walk test, MMRC = modified Medical Research Council scale, BMI = body mass 
 
386 index, SGRQ = St. George’s respiratory questionnaire, LINQ = Lung Information Needs 
 
387 Questionnaire. Values are represented as mean ± standard deviation. 
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388 
389 
Table 2 The LINQ domains and the total scores for each domain over three years 
 
LINQ domain Group Baseline Year 1 Year 2 Year 3 p-value 
Understanding U 1.06±0.68 1.13±0.50 1.06±0.57 1.25±0.58 .664 
COPD 
E
 
1.32±0.68 1.15±0.61 1.15±0.61 1.21±0.88 .547 
(range 0-4)      
U vs E 0.234 0.812 0.643 0.907 .710 
Medication U 0.75±0.93 0.31±0.60 0.44±0.73 0.38±0.62 .068 
(range 0-5) 
E
 
0.53±0.71 0.41±0.74 0.50±0.75 0.47±0.71 .786 
U vs E 0.490 0.620 0.782 0.633 .083 
Avoid U 2.81±1.76 3.38±1.82 2.31±1.74 2.44±2.00 .115 
exacerbation 
E
 
3.00±2.09 2.38±1.71 2.50±1.67 1.71±1.24 .000*** 
(range 0-6)      
U vs E 0.752 0.070 0.717 0.183 .002** 
Smoking U 0.00±0.00 0.00±0.00 0.00±0.00 0.06±0.25 .047* 
cessations 
E
 
0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.17 .325 
(range 0-3)      
U vs E - - - 0.617 .587 
Exercise U 1.50±0.89 0.87±0.50 0.94±0.44 0.94±0.44 .009** 
(range 0-5) 
E
 
1.29±0.87 1.03±0.52 0.88±0.48 0.91±0.57 .017* 
U vs E 0.459 0.318 0.699 0.963 .465 
Nutrition U 1.00±0.55 1.00±0.52 0.81±0.40 0.81±0.54 .024* 
(range 0-2) 
E
 
1.13±0.50 0.91±0.45 0.91±0.51 0.97±0.30 .654 
U vs E 0.335 0.552 0.501 0.173 .036* 
U 7.31±2.27 6.75±2.70 5.63±2.22 5.94±2.91 .067 
Total score 
E 
(range: 0-25) 
 
7.21±3.02 
 
5.94±2.37 
 
6.00±2.58 
 
5.35±2.10 
 
.003** 
U vs E 0.901 0.289 0.619 0.423 .458 
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391 
 
 
Definition of abbreviations: COPD = chronic obstructive pulmonary disease, LINQ = Lung 
 
392 Information Needs Questionnaire, Group U = usual care, Group E = exercise with ergo-cycle, 
 
393 U vs E = comparison between groups. 
 
394 Values are represented as mean ± standard deviation. 
 
395 
 
396 
* p< .05, **p< .01, ***p< .001 
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397 Table 3 Group comparisons over three years 
 
 
 
 Group Baseline Year 1 Year 2 Year 3 p-value 
FEV1% U 55.7±19.2 54.6±21.1 53.0±20.3 50.4±18.8 .001** 
predict, % 
E 48.3±14.5 48.2±16.4 48.1±17.9 47.9±17.1 .945 
 
U vs E 0.048 0.124 0.243 0.522 .016* 
6MWT Distance, m U 441.3±90.2 420.6±85.3 402.5±94.8 392.5±96.6 .000 
 
E 441.2±86.7 444.2±76.1 438.6±92.6 429.6±95.3 .265 
 
U vs E 0.996 0.219 0.116 0.110 .014* 
MMRC (range 0-4) U 1.4±1.0 1.5±1.1 1.7±1.3 1.9±1.2 .114 
 
E 1.5±1.0 1.6±0.7 1.6±0.9 1.7±1.0 .560 
 
U vs E 0.726 0.901 0.698 0.369 .543 
BMI U 21.1±3.5 20.7±3.3 20.6±3.1 20.4±3.4 .006** 
 
E 22.2±3.6 21.8±2.9 21.7±3.0 21.5±2.8 .083 
 
U vs E 0.178 0.137 0.116 0.098 .940 
BODE index U 2.0±1.5 2.3±1.8 2.8±1.9 3.1±1.7 .000*** 
(range 0-10) 
E 2.6±1.4 2.6±1.5 2.8±1.6 3.0±1.7 .011* 
 
U vs E 0.124 0.431 0.835 0.889 .118 
SGRQ (range0-100) U 36.0±17.5 37.7±15.5 36.0±16.3 35.9±17.1 .805 
 
E 36.6±11.2 35.2±11.8 39.5±14.6 38.4±14.2 .177 
 
U vs E 0.908 0.530 0.443 0.579 .289 
Number of U 1.2±0.8 1.0±0.8 1.0±0.8 1.1±0.9 .510 
exacerbations / year 
E
 
1.0±0.8 0.6±0.8 0.8±0.8 0.9±0.8 .009** 
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Number of 
hospitalization / year 
(Respiratory) 
 
Number of 
hospitalization / year 
(Other) 
 
398 
 
399 Definition of abbreviations: FEV1 = forced expiratory in 1 second, 6MWT = 6-minute walk 
 
400 test, MMRC = modified medical research council scale, BMI = body mass index, BODE 
 
401 index = body mass index, airflow obstruction, dyspnea and exercise capacity, SGRQ = St. 
 
402 George’s  respiratory  questionnaire,   Group   U   =  usual  care,  Group  E   =  exercise  with 
 
403 ergo-cycle, U vs E = comparison between groups. 
 
404 Values are represented as mean ± standard deviation. 
 
405 
 
406 
* p< .05, **p< .01, ***p< .001 
U vs E 0.532 0.057 0.436 0.229 .742 
U 0.1±0.4 0.1±0.3 0.0±0.0 0.2±0.5 .054 
E 0.2±0.4 0.1±0.2 0.1±0.4 0.1±0.4 .344 
U vs E 0.482 0.982 0.047 0.186 .066 
U 0.1±0.4 0.2±0.5 0.2±0.5 0.1±0.3 .614 
E 0.1±0.3 0.1±0.4 0.1±0.4 0.2±0.4 .226 
U vs E 0.186 0.880 0.746 0.028 .295 
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408 
Figure Legends 
 
409 
 
410 
Figure 1. Flow chart showing the distribution of participants throughout the study. 
 
411 Figure 2. Changes in the variables and total score of the BODE index over three years. 
 
412 A) At baseline, predicted FEV1 % was significantly lower in Group E (p=.016), and was 
 
413 maintained over the study period, whereas a marked decrease was observed in Group U 
 
414 (p=.001). B) Six-minute walking test distance (6MWTD) was significantly lower for Group 
 
415 U (p<.001) and worsened dramatically from baseline to the second year (p=.001), and the 
 
416 third year (p<.001). There was also a significant difference between the first year and the 
 
417 third year for Group U (p=.006). A significant difference was noted between Groups U and E 
 
418 from baseline to the third year (p=.014). C) The modified medical research council scale 
 
419 (MMRC) in each group worsened over three years, but there was no major difference 
 
420 between the groups from baseline to the third year. D) An increase was noted for the BODE 
 
421 index scores for Groups U and E from baseline to completion of the study, (p<.001 and 
 
422 p=.011, respectively); however, no difference was evident between the groups over three 
 
423 years. 
